Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to assess the safety and tolerability of oral OV101 (gaboxadol) in adult and adolescent subjects with Angelman syndrome. In addition, several exploratory efficacy outcome measures will be investigated.


Clinical Trial Description

Two dosing schedules of OV101 (gaboxadol) giving as once daily or twice daily dose will be assessed against placebo. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02996305
Study type Interventional
Source Ovid Therapeutics Inc.
Contact
Status Completed
Phase Phase 2
Start date January 2016
Completion date August 6, 2018

See also
  Status Clinical Trial Phase
Completed NCT00004351 - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes N/A
Completed NCT03235037 - Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome N/A
Completed NCT03644693 - Nutritional Formulation for Angelman Syndrome N/A
Completed NCT03358823 - Study on the Brain Network of Angelman Syndrome
Not yet recruiting NCT04768803 - Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity
Completed NCT02670694 - Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW N/A
Completed NCT00348933 - Dietary Supplements for the Treatment of Angelman Syndrome N/A
Completed NCT02056665 - Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome Phase 2
Completed NCT01281475 - A Trial of Levodopa in Angelman Syndrome Phase 2/Phase 3
Completed NCT00829439 - Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome Phase 1
Recruiting NCT03882918 - An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome Phase 2
Active, not recruiting NCT04259281 - A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome Phase 1/Phase 2
Completed NCT00296764 - Characterization of Angelman Syndrome
Active, not recruiting NCT03650569 - Angelman Syndrome Italian Registry
Recruiting NCT04103333 - Angelman Syndrome (AS) Biomarker Study Early Phase 1
Recruiting NCT04428281 - A Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of RO7248824 In Participants With Angelman Syndrome Phase 1
Recruiting NCT04507997 - Angelman Syndrome Natural History Study
Completed NCT03109756 - Single Dose Pharmacokinetic (PK) Study Phase 1
Recruiting NCT04863794 - A Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male Participants Phase 1
Completed NCT02381457 - SNP-based Microdeletion and Aneuploidy RegisTry (SMART)